May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG ... or redness of skin during or a few days after Imaavy infusion. Before or during treatment, patients ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

For details, see the “Before receiving Ultomiris” section. With myasthenia gravis, dysfunctional muscle ... begins with a loading dose. Two weeks after the loading dose, you’ll continue ...

Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with myasthenia gravis. Poster presented at: AMCP 2025; March 31-April 3 ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

Nicholas J. Silvestri, MD, describes how this year’s AAN meeting highlighted significant advances in myasthenia gravis, including improved diagnostics through cell-based assays that enhance ...

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.